江湖电竞比赛竞猜网址
ROVI
ES
-0.16
-0.34%
Closed
€ 46.70
| Previous Close |
|---|
| €46.86 |
Volume: 104K
65 Day Avg: 115.38K
46.30
Day Range
47.48
45.10
52 Week Range
74.90
Overview
ROVI Overview
Key Data
- Open €46.30
- Day Range 46.30 - 47.48
- 52 Week Range 45.10 - 74.90
- Market Cap €2.5B
- Shares Outstanding 54.02M
- Public Float 20.85M
- Beta N/A
- Rev. per Employee €422.06K
- P/E Ratio 14.00
- EPS €3.34
- Yield 1.66%
- Dividend €0.77
- Ex-Dividend Date Jul 5, 2022
- Short Interest N/A
- % of Float Shorted N/A
- Average Volume 115.38K
Performance
| 5 Day |
|
| 1 Month |
|
| 3 Month |
|
| YTD |
|
| 1 Year |
|
Analyst Ratings
Number of Ratings
10
Full Ratings
Recent News
Moderna signs on for another COVID-19 vaccine manufacturing deal
Shares of Moderna Inc. gained 0.5% in premarket trading on Thursday after the drugmaker announced another manufacturing deal for its still investigational COVID-19 vaccine. As part of the deal, Laboratorios Farmacéuticos ...
CVS Caremark, Deer Consumer, ETrade, Hasbro, Novavax
A roundup of stocks seeing significant moves in U.S. markets on Monday.
Novavax, Rovi end flu-vaccine-development plan
TEL AVIV (江湖电竞最新版比赛(江湖电竞投注app网站)) -- Novavax Inc., the Rockville, Md., biotech company focused on infectious diseases, said it ended talks aimed at a collaboration with Rovi Pharmaceuticals, the Madrid drugmaker, to develop Novavax...
Laboratorios Farmaceuticos Rovi S.A.
Laboratorios Farmaceúticos Rovi SA engages in the research, development, manufacture, and marketing of small molecule and specialty biologic drugs. It operates through the following business segments: Manufacturing, Marketing, and Other. The Manufacturing segment obtains its income from service contracts that relate to the finalization of the pharmaceutical product production process for external entities and the manufacture of products to be subsequently marketed by other group companies. The Marketing segment purchases and sells pharmaceutical products. The Other segment includes other services, research, and development activities that are not significant for the group. The company was founded on December 21, 1946 and is headquartered in Madrid, Spain.
Competitors
| Name | Chg % | Market Cap |
|---|---|---|
| Recordati S.p.A. |
|
€8.46B |
| Biotechnology Assets S.A. |
|
€5.82M |
| Lavipharm S.A. |
|
€8.68M |
| Almirall S.A. |
|
€1.62B |